Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: BIIB017 (peginterferon beta-1a); Drug: Interferon beta type 1a
Sponsor: Biogen
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
June 2, 2019ClinicalTrials.govComments OffInfections and Infectious DiseasesBeta1a | BIIB017 | Efficacy | Evaluate | Multiple | Participants | Pediatric | PegInterferon | Relapsingremitting | Safety | Sclerosis | Study | Tolerability | Treatment
Comments
